Loading...
Bilateral Trade Intelligence · $40.6K Total Trade · 1 Foreign Suppliers · 1 Indian Buyers · DGFT Verified · Updated March 2026
India imported $40.6K worth of pharmaceutical formulations from Yemen across 1 verified shipments, from 1 foreign suppliers to 1 Indian buyers. The top suppliers are AL-HILAL PHARMACY ($40.6K). The leading products are Omeprazole ($41K). Average shipment value: $40.6K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Omeprazole | $40.6K | 100.0% |
India imports 1+ pharmaceutical formulations from Yemen with a combined trade value of $40.6K. Key products include Omeprazole ($41K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 1 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Yemen, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Yemen buyers, regulatory requirements, and logistics for that specific product corridor. Products include Omeprazole ($41K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
1 Indian pharmaceutical companies export finished formulations to Yemen. Leading exporters include Al-hilal Pharmacy, . The top exporter accounts for 100.0% of total India–Yemen pharma exports. Source: Indian Customs (DGFT).
1 companies in Yemen import pharmaceutical formulations from India. Top buyers include S Kant Healthcare Limited, . The largest buyer accounts for 100.0% of India–Yemen pharma imports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Yemen and India has remained relatively underdeveloped over the past two decades. In 2019, Yemen imported pharmaceutical products worth $127.85 million, with India accounting for $29.28 million of this total. This indicates that India supplied approximately 22.9% of Yemen's pharmaceutical imports in that year. However, the specific data for the years 2022 to 2026 is not readily available, making it challenging to assess the evolution of this trade corridor during that period. The limited available data suggests that the trade volume has remained modest, with India maintaining a consistent share of Yemen's pharmaceutical imports.
Yemen's contribution to India's pharmaceutical imports is minimal. In 2022, India's total pharmaceutical imports were valued at $3.2 billion, with Yemen's share being a mere $41,000. This underscores Yemen's negligible role in India's pharmaceutical import landscape. The single product imported from Yemen during this period was Omeprazole, a medication used to treat gastroesophageal reflux disease and stomach ulcers. The importation of this product indicates that Yemen's pharmaceutical exports to India are limited to specific, niche products.
Between 2024 and 2026, there have been no significant policy changes or trade agreements between India and Yemen concerning pharmaceutical imports. The Central Drugs Standard Control Organisation (CDSCO) in India has maintained its existing regulatory framework for the importation of pharmaceutical products. Similarly, Yemen's National Drug Regulatory Authority continues to uphold its standards for pharmaceutical exports. The lack of substantial developments suggests a stagnant trade relationship in the pharmaceutical sector between the two nations during this period.
===BLOCK===
IMPORT_REGULATORY
Registration process, GMP requirements, import documentation
For a Yemeni pharmaceutical company to register a product for import into India, it must navigate the CDSCO's regulatory process. The first step involves registering on the CDSCO's SUGAM portal, which is designed to streamline the approval process for manufacturers. Applicants are required to submit an Integrated Registration Form (IRF) along with necessary documents, including an undertaking form, valid address proof of the firm, and a valid ID proof of the authorized person. Once the application is submitted, it undergoes verification by CDSCO Headquarters. This process ensures that the applicant complies with all regulatory requirements set forth by the CDSCO.
After successful registration on the SUGAM portal, the applicant must submit an application for product registration. This application should include detailed product information, such as composition, manufacturing process, and evidence of compliance with Good Manufacturing Practices (GMP). The CDSCO evaluates the application to ensure that the product meets the safety, efficacy, and quality standards required for the Indian market. The timeline for this process can vary, but it typically ranges from several months to over a year, depending on the complexity of the product and the completeness of the application.
India requires that pharmaceutical products imported from Yemen adhere to stringent GMP standards. The CDSCO mandates that manufacturing sites comply with WHO-GMP guidelines to ensure product quality and safety. Yemeni manufacturers seeking to export to India must provide evidence of WHO prequalification, which serves as a testament to their adherence to international manufacturing standards. The CDSCO conducts inspections of manufacturing facilities to verify compliance with these standards. These inspections assess various aspects, including facility cleanliness, equipment calibration, personnel training, and documentation practices. Only products from manufacturers that pass these inspections are granted approval for import into India.
To import pharmaceutical products into India, Yemeni companies must obtain an import license, commonly referred to as Form 10. This license authorizes the importation of specific pharmaceutical products and is issued by the CDSCO. Additionally, a registration certificate is required, which confirms that the product has been approved for sale in India. A No Objection Certificate (NOC) from the manufacturer in Yemen may also be necessary, especially if the product is being imported by an agent or distributor. A test license is required for the importation of drugs for testing, analysis, or clinical trial purposes. The customs procedures involve submitting these documents to Indian customs authorities, who verify their authenticity and compliance with Indian regulations before allowing the goods to enter the country.
===BLOCK===
IMPORT_TRENDS
Dominant categories, emerging opportunities, and demand drivers
India's pharmaceutical imports from Yemen are limited to specific products, with Omeprazole being the only item imported in 2022. This indicates that Yemen's pharmaceutical exports to India are concentrated in a narrow range of products, primarily focusing on generic medications. The lack of diversity in product categories suggests that Yemen's pharmaceutical industry has yet to establish a significant presence in the Indian market. The dominance of a single product category reflects the challenges Yemeni manufacturers face in meeting the diverse demands of the Indian pharmaceutical market.
The importation of Omeprazole from Yemen to India highlights the potential for niche market opportunities. However, the limited volume and range of products suggest that Yemen's pharmaceutical industry has yet to introduce innovative or specialty products that could cater to unmet needs in the Indian market. The absence of novel formulations or advanced therapies from Yemen indicates a gap in the country's pharmaceutical export capabilities, which could be a barrier to expanding its presence in India's competitive pharmaceutical sector.
The minimal importation of pharmaceutical products from Yemen to India can be attributed to several factors. Patent protection in India ensures that many innovative drugs are not available for import. Additionally, technology gaps and quality requirements pose challenges for Yemeni manufacturers seeking to meet the stringent standards set by the CDSCO. The disease burden in India, which necessitates a diverse range of pharmaceutical products, further complicates the integration of Yemeni products into the Indian market. These factors collectively contribute to the limited demand for Yemeni pharmaceutical imports in India.
===BLOCK===
IMPORT_POLICY
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes the Most Favored Nation (MFN) tariff rates, basic customs duty, Integrated Goods and Services Tax (IGST), and health cess. The MFN tariff rates are applied to imports from countries with which India does not have a Free Trade Agreement (FTA). The basic customs duty is levied on the value of the imported goods, while the IGST is applicable to the supply of goods and services. The health cess is an additional levy imposed on certain imported goods to fund health-related initiatives. These tariffs and taxes collectively impact the pricing and competitiveness of imported pharmaceutical products in the Indian market.
As of March 2026, there is no Free Trade Agreement (FTA) between India and Yemen. Consequently, Yemeni pharmaceutical products are subject to the standard MFN tariff rates and import duties applicable to non-FTA countries. There have been no significant bilateral negotiations or regional trade agreements, such as the Regional Comprehensive Economic Partnership (RCEP), that would offer preferential duty rates for Yemeni exports to India. The absence of such agreements limits the potential for Yemeni pharmaceutical products to gain a competitive edge in the Indian market.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and ensures that only genuine innovations receive patent protection. This provision can impact the availability of certain pharmaceutical products for import, as patents may restrict the entry of generic versions into the market. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines in India, including imported drugs, to ensure affordability. While this can benefit consumers, it may also affect the profitability of imported pharmaceutical products, potentially deterring suppliers from entering the market.
===BLOCK===
IMPORT_LOGISTICS
Shipping routes, port infrastructure, cold chain compliance
The primary shipping route for pharmaceutical imports from Yemen to India is by sea. The journey typically involves transporting goods from Yemeni ports to major Indian ports such as Mumbai, Chennai, and Kolkata. Transit times can vary depending on the specific ports of departure and arrival, as well as the shipping line's schedule. Sea freight is generally preferred for bulk shipments due to its cost-effectiveness, but it requires careful planning to ensure timely delivery.
Yemen's key export ports include Aden and Hodeidah, which handle a significant portion of the country's maritime trade. In India, major import ports such as Mumbai, Chennai, and Kolkata are equipped to handle pharmaceutical shipments. These ports have the necessary infrastructure to manage the importation of pharmaceutical products, including storage facilities that comply with Good Distribution Practices (GDP) and cold chain requirements. The efficiency and capacity of these ports are crucial for ensuring the timely and safe delivery of pharmaceutical imports.
Upon arrival at Indian ports,
India exported pharmaceuticals worth $40.6K to Yemen across 1 verified shipments.
1. AL-HILAL PHARMACY — $40.6K. Total: 1 suppliers.
1. S KANT HEALTHCARE LIMITED — $40.6K. 1 buyers total.
1. Omeprazole ($40.6K, 100.0%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $40.6K corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$40.6K per consignment across 1 shipments.
1 Indian companies. Largest: AL-HILAL PHARMACY with $40.6K.
TransData Nexus covers 1 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 1 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Exporters
1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists